GLS Stock Overview
Engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Glenmark Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹850.70 |
| 52 Week High | ₹972.00 |
| 52 Week Low | ₹596.00 |
| Beta | 0.14 |
| 11 Month Change | 0.97% |
| 3 Month Change | 4.39% |
| 1 Year Change | 28.83% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 13.65% |
Recent News & Updates
Shareholder Returns
| GLS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.4% | 2.2% | -1.0% |
| 1Y | 28.8% | 46.7% | 43.6% |
Return vs Industry: GLS underperformed the Indian Pharmaceuticals industry which returned 46.7% over the past year.
Return vs Market: GLS underperformed the Indian Market which returned 43.6% over the past year.
Price Volatility
| GLS volatility | |
|---|---|
| GLS Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: GLS has not had significant price volatility in the past 3 months.
Volatility Over Time: GLS's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,824 | Yasir Rawjee | www.glenmarklifesciences.com |
Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies.
Glenmark Life Sciences Limited Fundamentals Summary
| GLS fundamental statistics | |
|---|---|
| Market cap | ₹104.23b |
| Earnings (TTM) | ₹4.47b |
| Revenue (TTM) | ₹22.97b |
23.3x
P/E Ratio4.5x
P/S RatioIs GLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLS income statement (TTM) | |
|---|---|
| Revenue | ₹22.97b |
| Cost of Revenue | ₹10.42b |
| Gross Profit | ₹12.55b |
| Other Expenses | ₹8.08b |
| Earnings | ₹4.47b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 36.48 |
| Gross Margin | 54.65% |
| Net Profit Margin | 19.46% |
| Debt/Equity Ratio | 0% |
How did GLS perform over the long term?
See historical performance and comparison